“Biotech firm Novavax said Monday its Covid-19 vaccine was shown to be safe and 90.4% effective overall in a phase three clinical trial of nearly 30,000 participants across the United States and Mexico.
“Additionally, it said the two-dose vaccine was found to be 100% effective in preventing moderate and severe disease and 93% effective against some variants. The company said it plans to file for authorization with the Food and Drug Administration in the third quarter.
“The late-stage trial “confirms that NVX-CoV2373 offers an encouraging tolerability and safety profile,” Dr. Gregory Glenn, Novavax’s president of research and development, said in a press release.
““These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus.””
Read more at CNBC
